Scott Eggener

The @UCLAHealth Urology Spring 2026 newsletter is out. Take a look at program highlights, alumni profiles, and update from the chair. uclahealth.org/sites/default/…

@DrSpratticus @ChapinMD @urotoday @UroOnc @Uroweb @wandering_gu @BogdanaSchmidt @CanesDavid @DrMLChua @HimanshuNagarMD @AmarUKishan @piet_ost @alison_tree @declangmurphy Highest value (by far) is estimating prostate size (PSAD) in order to risk stratify whether they even need MRI, secondary biomarker, or biopsy. And do occasionally find induration/nodule that is potentially meaningful

#EAU26 DRE not recommended for asymptomatic men. What are people’s thoughts on need for routine DRE in era of MRI? @ChapinMD @urotoday @UroOnc @Uroweb @wandering_gu @BogdanaSchmidt @CanesDavid @DrMLChua @HimanshuNagarMD @AmarUKishan @piet_ost @alison_tree @declangmurphy

Prof Hugosson: Göteborg trial with 30 year outcomes! NND falls to -6-, with greatest benefit for men 50-59 at randomization. Despite no image guidance, high overdx, and suboptimal tx. Best evidence we have re: the evidence for #prostatecancer screening. Get tested! #eau26 @uroweb

A cancer diagnosis can push people to crime economist.com/graphic-detail… from The Economist

@DrSpratticus Valuable comments @Spratticus Often, not always, less is more Myriad reasons those studies aren’t routinely done Come join those of us who have tried contributing data to this essential conversation

#GU26 and #fengsymposium was a blast to see progress. Hoping it eventually moves away from San Fran 😁. Another red eye on the books back home. My observations from PCa sessions: - the field continues to push for over tx and many fail to recognize high risk dz is not high risk anymore for most patients. Enzarad negative, Rtog 0924 neg, ascend-RT neg for MFS/OS, peace2 neg. RT+ADT plenty for most. Many need even less. Select trials paving the way. - for mHSPC not all patients need doublet let alone triplet; age matters - continuous ADT can often be more harmful than helpful now with MDT -most BCR patients post RP do not need ADT—> get biomarker testing to help -many have jumped on bandwagon that OS too hard to improve and settling for early non-surrogate endpoints; peace3 should remind us it’s possible -sequential PARPi /Abi often just as good as combination -early germline/somatic testing for all high risk disease remains without data to support it; even testing in mHSPC unclear benefit as can give PARPi in mCRPC setting (earlier not better than later). -actinium RLT promising but toxicity remains concern -neoadj before RP remains largely ineffective, adds costs and toxicity and most still need postop tx.

Interested in catapulting your career in a 1 year fellowship with world-class urologists and an emphasis on innovative imaging, diagnostic, and focal PrCa treatments? Availability July 2026

Happy #matchday soon to be Urologists Congrats to soon-to-be-doctors Bettencourt, Lerman, Borrell, and Yoffe We look forward to welcoming you to the @UCLAHealth Urology family this summer. For those who didn't receive the news they hoped for, your journey is still beginning.

A powerful essay on a perennial surgical experience, by an extraordinarily talented and evocative author (urologist): @TaylorGoodstein ascopubs.org/doi/full/10.12…

Productive and fun day for @UclaUrology Faculty vs residents in volleyball Plus, look who lost a wager.....

Our annual state of the art is just around the corner. Whether you are an alumni, colleague practicing nearby, or traveling for your CME we hope you join us for this immersive course. There is content for all. Info and registration below web.cvent.com/event/159d0f39…

We should all listen to more music...... Jealous of those who create or play: @CanesDavid @JBMatthews @endourologyucsd Music Versus Cognitive Behavioral Therapy for Anxiety in Cancer Survivors: A Randomized Clinical Trial | Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Correction: these were both listed on JAMA Surgery Most Viewed of 2025

Fascinatingly counterintuitive If observation is indeed true, many potential explanations (P.S. article in same issue shows surgeon mortality is higher than non-surgeon physicians) Association Between Surgeon Stress and Major Surgical Complications jamanetwork.com/journals/jamas…

Opportunity for a new Director of the Institute of Urologic Oncology (IUO) at UCLA (uclahealth.org/departments/ur…) Seeking the best and brightest (internally/externally) to lead this multi-D clinical, academic, and educational engine To learn more and apply: recruit.apo.ucla.edu/JPF10718

Always used hemostatic agents for PNx, then used for 50% of cases during the trial, now will only use very selectively.....lots of gratitude to the team and patients who made this happen auajournals.org/doi/10.1097/JU…

It's that time of year.....if you dig high quality urology speakers, world-class skiing, and memorable camaraderie, consider Aspen Urological Conference Feb 9-12 aspenuro.org

With prototypical heart and humanity, a moving piece by Mark Litwin from @UclaUrology The Three O’Clock Patient jamanetwork.com/journals/jama/…

As reported in @nytimes by @ginakolata with a shout out to Lenny Marks from @UclaUrology: provocative data on screening, diagnosis, incidence, mortality of many common cancers and how it should impact practice/policy jamanetwork.com/journals/jamai…

Remains one of the cheapest/easiest ways to minimize unnecessary testing, biopsy, diagnosis, or treatment: repeat a newly elevated PSA (without empiric abx) jamanetwork.com/journals/jamao…

Compelling editorial, data-based, from @UclaUrology Richard Boxer on why funding cancer research/NCI is valuable ascopost.com/issues/novembe…